LeonaBio, Inc. (LONA): R&D Expense
$17.50M
Year ended 2025-12-31
$33.50M
Trailing 12 months to 2026-06-30
-34.2%
3-year compound annual growth
+5.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $17.50M | -75.2% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $70.68M | -24.6% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $93.79M | +52.6% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $61.46M | +43.6% | 2024-02-22, From 2022-01-01 |
| 2021-12-31 | $42.79M | +222.1% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $13.29M | +250.3% | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | $3.79M | n/a | 2021-03-25, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| LeonaBio, Inc. (LONA) | 2025-12-31 | $17.50M | -75.2% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $60.22M | +10.8% |
| Quince Therapeutics, Inc. (QNCX) | 2025-12-31 | $35.38M | +90.3% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $69.45M | -1.2% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $29.36M | +39.0% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $19.57M | +50.9% |
| Anavex Life Sciences Corp. (AVXL) | 2025-09-30 | $37.59M | -10.1% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $1.87M | -52.4% |
| Armata Pharmaceuticals, Inc. (ARMP) | 2025-12-31 | $23.72M | -31.1% |
Compare LONA, ATYR, QNCX, ALGS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗